Alluvi BPC-157 & TB-500 40mg: Research Product and Batch Guide

The Alluvi BPC-157 & TB-500 40mg listing concerns a combined research product. This guide explains what a BPC-157 and TB-500 blend means, which product details researchers may review and why promotional recovery claims require caution.

What are BPC-157 and TB-500?

BPC-157 and TB-500 are names used for research peptides discussed in experimental contexts. Products carrying these names are not licensed UK medicines for injury treatment, tissue repair or recovery. Research discussion should not be presented as clinical proof.

What does a 40mg blend describe?

A stated total such as 40mg does not explain the amount of each component by itself. The listing should identify the composition, total quantity, batch reference and format. Readers should avoid assuming that a combined total means equal quantities.

Documentation to review

• Exact product and component names.
• Stated amount of each component.
• Batch or lot number.
• Certificate of Analysis matching the batch.
• Test method, date and laboratory.
• Storage and research-use statement.

Why research notices matter

“Research and development use” defines a product’s intended context. It does not provide instructions for self-administration or permission to make treatment claims. Buyers and institutions remain responsible for applicable laws, facility rules and safe laboratory practice.

Reviewing the Alluvi product range

The Alluvi Healthcare UK homepage provides the wider product overview. Always use the individual product record for current composition, documentation and availability.

Continue your quality checks

Read our guide on Certificates of Analysis and peptide batch testing, then review the Tirzepatide and Retatrutide comparison.

For research information only. This article does not provide medical advice or human-use instructions.